Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592421 · ClinicalTrials.gov registry record · Phase 3
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
A Phase 3 study of Type II Diabetes Mellitus, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02592421: Completed Phase 3 study of Type II Diabetes Mellitus, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02592421 is a Phase 3 study of Type II Diabetes Mellitus that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 30 participants, below the 170-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02592421, a Phase 3 study of Type II Diabetes Mellitus, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
Primary Outcome
Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose concentration
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-10-23 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 3 |
What the finished NCT02592421 record still lists
NCT02592421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 170-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Type II Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02592421 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02592421 about?
NCT02592421 is a clinical study titled "SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2". In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
What is the current status of trial NCT02592421?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2015-10-23. Estimated completion is 2019-10-31.
What conditions does trial NCT02592421 study?
This clinical trial studies the following conditions: Type II Diabetes Mellitus.
What interventions are being tested in trial NCT02592421?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02592421?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02592421 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type II Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
RECRUITING · Phase 2
-
The GRoceries Aimed at Increasing Nutrition Study
RECRUITING · NA
-
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
RECRUITING · Phase 1
-
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
COMPLETED · NA
-
Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
COMPLETED · Phase 2
-
The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI